Emergo has just received $3.5 million in equity backing from 77 investors. The money will be used for a new clinical study to see how its new therapy works on patients with flu-like symptoms,
Read More
Emergo is developing a single drug candidate, norketotifen, for treating flu and flu-like illnesses. The compound works by modulating the immune system’s response to viral infection.
Read MoreMoise Khayrallah, Ph.D., is a serial entrepreneur with a Midas touch. Three biopharmaceutical start-ups he co-founded in recent years were quickly sold to larger companies for more than $400 million after he and his teams built their value from scratch. Will Emergo be number four?
Read MoreAn all-star list of Triangle investors is backing Durham pharmaceutical startup Emergo Therapeutics with $12 million in venture capital.
Read More
